Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease

Journal of Neural Transmission

Volumn 118, Issue 6, 2011, Pages 865-875

  Zádori, Dénes ^a   Nyiri, Gábor ^b   Szonyi, András ^b   Szatmári, István ^c   Fülöp, Ferenc ^c   Toldi, József ^c   Freund, Tamás F ^b   Vécsei, László ^a   Klivényi, Péter ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Huntington's disease; Kynurenic acid analogue; N171 82Q; Neuroprotection; Stereology; Transgenic mice

Indexed keywords

KYNURENIC ACID DERIVATIVE; N (2 N,N DIMETHYLAMINOETHYL) 4 OXO 1H QUINOLINE 2 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; EXCITOTOXICITY; FEMALE; HISTOPATHOLOGY; HUNTINGTON CHOREA; MALE; MOUSE; NERVE CELL; NEUROANATOMY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; WEIGHT REDUCTION;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; HUNTINGTON DISEASE; KYNURENIC ACID; MALE; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS;

EID: 79955661135     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0573-6     Document Type: Article

References (53)

1. Bahn A, Ljubojevic M, Lorenz H, Schultz C, Ghebremedhin E, Ugele B, Sabolic I, Burckhardt G, Hagos Y (2005) Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol 289:C1075-C1084 (Pubitemid 41456824)
2. Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED (1990) Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 55:1327-1339
3. Birch PJ, Grossman CJ, Hayes AG (1988) Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. Eur J Pharmacol 151:313-315
4. Borza I, Kolok S, Galgóczy K, Gere A, Horváth C, Farkas S, Greiner I, Domány G (2007) Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett 17:406-409 (Pubitemid 46073751)
5. Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, Raymond LA (1999) Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 72:1890-1898 (Pubitemid 29185991)
6. Connick JH, Stone TW (1988) Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo. Br J Pharmacol 93:868-876 (Pubitemid 18093395)
7. Coyle JT, Schwarcz R (1976) Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea. Nature 263:244-246
8. Csillik A, Knyihár E, Okuno E, Krisztin-Péva B, Csillik B, Vécsei L (2002) Effect of 3-nitropropionic acid on kynurenine aminotransferase in rat brain. Exp Neurol 177:233-241 (Pubitemid 35356836)
9. de Carvalho LP, Bochet P, Rossier J (1996) The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int 28:445-452 (Pubitemid 26120215)
10. DiFiglia M (1990) Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 13:286-289 (Pubitemid 20193460)
11. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22:1592-1599 (Pubitemid 35386278)
12. Fonnum F, Storm-Mathisen J, Divac I (1981) Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience 6:863-873 (Pubitemid 11101763)
13. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith OR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007-2017
14. Fülöp F, Szatmári I, Vámos E, Zádori D, Toldi J, Vécsei L (2009) Synthesis, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem 16:4828-4842
15. Fusco FR, Chen Q, Lamoreaux WJ, Figueredo-Cardenas G, Jiao Y, Coffman JA, Surmeier DJ, Honig MG, Carlock LR, Reiner A (1999) Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J Neurosci 19:1189-1202 (Pubitemid 29088902)
16. Gárdián G, Vécsei L (2004) Huntington's disease: pathomechanism and therapeutic perspectives. J Neural Transm 111:1485-1494 (Pubitemid 39468401)
17. Gárdián G, Browne SE, Choi DK, Klivényi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280:556-563 (Pubitemid 40165021)
18. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 17:455-461 (Pubitemid 39574879)
19. Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R (2006) Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 23:190-197 (Pubitemid 43922462)
20. Harris CA, Miranda AF, Tanguay JJ, Boegman RJ, Beninger RJ, Jhamandas K (1998) Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br J Pharmacol 124:391-399 (Pubitemid 28248031)
21. Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL (2009) In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci 29:3200-3205
22. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases nonalpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463-7473 (Pubitemid 32904945)
23. Jauch D, Urbańska EM, Guidetti P, Bird ED, Vonsattel JP, Whetsell WO Jr, Schwarcz R (1995) Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J Neurol Sci 130:39-47
24. Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319-1328 (Pubitemid 19085960)
25. Klivényi P, Bende Z, Hartai Z, Penke Z, Németh H, Toldi J, Vécsei L (2006) Behaviour changes in a transgenic model of Huntington's disease. Behav Brain Res 169:137-141 (Pubitemid 43277479)
26. Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB Jr, Young AB (1995) NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 15:5297-5307
27. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, Wu DC, Lu J, Tymianski M, Craig AM, Wang YT (2007) NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27:2846-2857 (Pubitemid 46438991)
28. * nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 80:1071-1078 (Pubitemid 34809959)
29. Masuda N, Peng Q, Li Q, Jiang M, Liang Y, Wang X, Zhao M, Wang W, Ross CA, Duan W (2008) Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol Dis 30:293-302
30. McGeer EG, McGeer PL (1976) Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 263:517-519
31. McNamara FN, Clifford JJ, Tighe O, Kinsella A, Drago J, Croke DT, Waddington JL (2003) Congenic D1A dopamine receptor mutants: ethologically based resolution of behavioural topography indicates genetic background as a determinant of knockout phenotype. Neuropsychopharmacology 28:86-99
32. Muir KW (2006) Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 6:53-60 (Pubitemid 43103819)
33. Perkins MN, Stone TW (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247:184-187 (Pubitemid 12028646)
34. Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R (2006) Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease. Exp Neurol 197:31-40 (Pubitemid 41817219)
35. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing mutant N-terminal fragment of huntingtin. Hum Mol Gen 8:397-407 (Pubitemid 29097327)
36. Schmitt ML, Graeff FG, Carobrez AP (1990) Anxiolytic effect of kynurenic acid microinjected into the dorsal periaqueductal gray matter of rats placed in the elevated plus-maze test. Braz J Med Biol Res 23:677-679 (Pubitemid 20294258)
37. Schmitz C, Schuster D, Niessen P, Korr H (1999) No difference between estimated mean nuclear volumes of various types of neurons in the mouse brain obtained on either isotropic uniform random sections or conventional frontal or sagittal sections. J Neurosci Methods 88:71-82 (Pubitemid 29238228)
38. Schwarcz R (2004) The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 4:12-17 (Pubitemid 38145832)
39. Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ (2010) Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol 90:230-245
40. Smith Y, Raju DV, Pare JF, Sidibe M (2004) The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci 27:520-527 (Pubitemid 39149820)
41. Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, Sporn M, Dumont M, Beal MF (2010) Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med 49:147-158
42. Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72:411-412 (Pubitemid 11081065)
43. Tavares RG, Tasca CI, Santos CE, Alves LB, Porciúncula LO, Emanuelli T, Souza DO (2002) Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 40:621-627 (Pubitemid 34246240)
44. Thompson PD, Berardelli A, Rothwell JC, Day BL, Dick JP, Benecke R, Marsden CD (1988) The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 111:223-244
45. Vámos E, Vörös K, Zádori D, Vécsei L, Klivényi P (2009a) Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. J Neural Transm 116:1079-1086
46. Vámos E, Párdutz Á, Varga H, Bohár Z, Tajti J, Fülöp F, Toldi J, Vécsei L (2009b) L-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology 57:425-429
47. Vámos E, Fejes A, Koch J, Tajti J, Fülöp F, Toldi J, Párdutz Á, Vécsei L (2010) Kynurenate derivative attenuates the nitroglycerininduced CamKIIalpha and CGRP expression changes. Headache 50:834-843
48. van Vugt JP, van Hilten BJ, Roos RA (1996) Hypokinesia in Huntington's disease. Mov Disord 4:384-388 (Pubitemid 26235775)
49. Vécsei L, Beal MF (1991) Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. Eur J Pharmacol 196:239-246
50. Walker FO (2007) Huntington's disease. Semin Neurol 27:143-150 (Pubitemid 46564475)
51. West NJ (2002) Design-based stereological methods for counting neurons. Prog Brain Res 135:43-51
52. Zádori D, Klivényi P, Vámos E, Fülöp F, Toldi J, Vécsei L (2009a) Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm 116:1403-1409
53. Zádori D, Geisz A, Vámos E, Vécsei L, Klivényi P (2009b) Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol Biochem Behav 94:148-153